Table 1. Characteristics of three cognitive groups as a function of Aspirin using status.
| Aspirin using status | |||
|---|---|---|---|
| Characteristics | Non-aspirin users | Aspirin users | P values |
| NC (n = 509) | |||
| Sample size, n | 310 | 199 | / |
| Age, years | 73.4 ± 6,14 | 74.4 ± 5.89 | 0.08 |
| Education, years | 16.4 ± 2.72 | 16.5 ± 2.53 | 0.75 |
| APOE4 carriers, n (%) | 82 (26.5) | 59 (29.6) | 0.43 |
| Females, n (%) | 185 (59.7) | 80 (40.2) | < 0.001 |
| Hypertension, n (%) | 97 (31.3) | 79 (39.7) | 0.052 |
| Diabetes, n (%) | 13 (4) | 12 (6) | 0.35 |
| MMSE | 29.1 ± 1.1 | 29 ± 1.1 | 0.51 |
| MCI (n = 985) | |||
| Sample size, n | 586 | 399 | / |
| Age, years | 72.4 ± 8.03 | 73.7 ± 6.9 | 0.005 |
| Education, years | 15.9 ± 2.87 | 16.2 ± 2.67 | 0.08 |
| APOE4 carriers, n (%) | 297 (50.7) | 204 (48.9) | 0.6 |
| Females, n (%) | 268 (45.7) | 133 (33.3) | < 0.001 |
| Hypertension, n (%) | 192 (32.8) | 169 (42.4) | < 0.001 |
| Diabetes, n (%) | 36 (6.1) | 34 (8.5) | 0.15 |
| The use of AD medications a, n (%) | 161 (27.5) | 118 (29.6) | 0.47 |
| MMSE | 27.6 ± 1.82 | 27.6 ± 1.86 | 0.9 |
| AD (n = 372) | |||
| Sample size, n | 231 | 141 | |
| Age, years | 74.3 ± 8.22 | 75.5 ± 7.4 | 0.15 |
| Education, years | 15.1 ± 3.05 | 15.4 ± 2.7 | 0.31 |
| APOE4 carriers, n (%) | 152 (65.9) | 97 (68.8) | 0.55 |
| Females, n (%) | 113 (48.9) | 51 (36.2) | 0.02 |
| Hypertension, n (%) | 95 (41.1) | 50 (35.5) | 0.28 |
| Diabetes, n (%) | 13 (5.6) | 14 (9.9) | 0.12 |
| The use of AD medications a, n (%) | 177 (76.6) | 105 (74.5) | 0.64 |
| MMSE | 23.2 ± 2.1 | 23 ± 2.2 | 0.5 |
a A subject was regarded as using AD medication if he or she received one of these AD medications, such as Donepezil, Memantine, Galantamine and Rivastigmine.
Abbreviations: CN: normal cognition; MCI: mild cognitive impairment; AD: Alzheimer’s disease; MMSE: mini-mental state examination.